Back to All

ASCO Daily Highlights Day 1

3 June, 2023

The ASCO meeting in Chicago each year is a critical calendar date for announcing new advancements and updated within the oncology industry. Our team of precision medicine experts are there in person absorbing the research presented and have picked their top three highlights from day one of the conference on Friday 2nd June.

1. The importance of IHC-based test in the era of NGS-based molecular profiling test.

MET-IHC, but not molecular profiling (eg. MET amplification) identify potential responsive patients in amivantamab plus lazertinib combined treatment.*

*Source: abstract#9013 talk “Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS”.

2. Predictive biomarker/new strategies were identified to predict treatment outcomes in Sarcoma.

ctDNA assay based MRD (NGS or ddPCR-based platforms), and histopathological response (IHC-based platforms) all show promising results in serve as predictive biomarker for identifying subgroup patients who can benefit from adjuvant systemic therapy (AST) (eg. neoadjuvant radiotherapy (RT) or chemotherapy (ChT)).*

*Source: abstract#11509 talk “Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS)”; abstract#11510 talk “The clinical value of tumor-informed minimal residual disease detection in sarcoma”; abstract #11511 talk “Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial”; abstract #11512 talk “Deep learning with whole slides images to predict histological response to neoadjuvant chemotherapy in patients with resectable high grade soft-tissue sarcomas: A multicenter study”.

3. Recommended testing strategies for evaluating c-MET protein overexpression and MET gene amplification are passed onto oncology clinicians to assist accurate targeted treatment prescription to NSCLC patients.*

*Source: Premium Ancillary educational events supported by an educational grant from AbbVie, “Mastering MET and cMET and recognizing their role in advanced NSCLC”

Keen to know more about how our precision medicine expert team can support your commercialzation strategy? Contact us here: Contact Us - Diaceutics

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny